v3.25.4
Segment Reporting
12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
Segment Reporting
Note 11—Segment Reporting
 
Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker (“CODM”), or decision-making group, in deciding how to allocate resources in assessing performance. Nuwellis has one reportable segment: fluid overload. The Company is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow® and the Aquadex SmartFlow® systems (collectively the “Aquadex System”). The Company recognizes this medical device business as one reporting segment. The Company’s CODM is the chief executive officer.
 
The accounting policies of the fluid overload segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for the fluid overload segment based on net loss, which is reported on the statement of operations as consolidated net loss. The measure of segment assets is reported on the balance sheet as total consolidated assets. The company does not have any intra-entity sales or transfers.
 
The CODM uses cash forecast models in deciding how to invest into the fluid overload segment. Such cash forecast models are reviewed to assess the entity-wide operating results and performance. Net loss is used to monitor budget versus actual results. Monitoring budgeted versus actual results is used in assessing performance of the segment and in establishing management’s compensation, along with cash forecast models.
The table below summarizes the significant expense categories regularly reviewed by the CODM for the years ended December 31, 2025, and 2024:
 
           
 
Year Ended
 December 31,
 
(in thousands)
  2025     2024  
Revenue
 $8,270   $8,740 
Gross Profit
  5,124    5,676 
Gross profit %
  62.0%   64.9%
Operating expenses:
         
General and administrative
  5,803    5,637 
Sales and Marketing
  6,703    6,254 
Development
  1,296    1,645 
Clinical, Quality, Regulatory
  2,301    2,650 
Total Expenses
  16,103    16,186 
Stock-Based Compensation
  127    478 
Other Expense
  6,415    177 
Net loss
  (17,521   (11,165